| [1] |
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4):252-264.
|
| [2] |
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nature Med, 1999, 5(12), 1365-1369.
|
| [3] |
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nature Med, 2002, 8(8), 793–800.
|
| [4] |
Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1(B7-H1) augments human tumor-specific T cell responses in vitro[J]. Int J Cancer, 2006, 119(2):317-327.
|
| [5] |
Costa R, Carneiro BA, Agulnik M, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials[J]. Oncotarget, 2017, 8(5):8910-8920.
|
| [6] |
Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy[J]. J Immunother Cancer, 2016, 16(4):50.
|
| [7] |
Läubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma[J]. J Immunother Cancer, 2015, 21(3):11.
|
| [8] |
Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60(6):210-225.
|
| [9] |
Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies[J]. N Engl J Med, 2016, 375(15):1457-1467.
|
| [10] |
Grabie N, Gotsman I, DaCosta R, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart[J]. Circulation, 2007, 116(18):2062-2071.
|
| [11] |
Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis[J]. J Immunol, 2012, 188(10):4876-4884.
|
| [12] |
Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice[J]. Science, 2001, 291(5502):319-322.
|
| [13] |
Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice[J]. Nat Med, 2003, 9(12):1477-1483.
|
| [14] |
Goser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune in- flammation in the myocardium[J]. Circulation, 2006, 114(16):1693.
|
| [15] |
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application[J]. Int Immunol, 2007, 19(7):813-824.
|
| [16] |
Lucas JA, Menke J, Rabacal WA, et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice[J]. J Immunol, 2008, 181(4):2513-2521.
|
| [17] |
Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice[J]. Int Immunol, 2010, 22(6):443-452.
|
| [18] |
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines[J]. European Heart Journal, 2016, 37(36):2768-2801.
|
| [19] |
Bielecka-Dabrowa A, Mikhailidis DP, Hannam S, et al. Takotsubo cardiomyopathy-the current state of knowledge[J]. Int J Cardiol, 2010, 142(2):120-125.
|